{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:09:26Z","timestamp":1765598966802,"version":"3.48.0"},"reference-count":51,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,3,27]]},"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>No consensus exists on the associations between adjuvant treatment with bisphosphonates and cancer recurrence risk among patients with primary early-stage cancers. We plan to perform a comprehensive systematic review, study-level meta-analysis and trial sequential analysis of randomised controlled trials to comprehensively summarise evidence of the bisphosphonate treatment for difference cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analyses<\/jats:title>\n                    <jats:p>We will report our results according to the PRISMA guideline. The primary outcomes include any cancer recurrence and bone metastasis and secondary outcomes include events of local recurrence, regional recurrence or non-skeletal distant metastasis, disease-free survival and overall survival. We will perform systematic electronic searches and other manual searches. To be conservative, all statistical analyses will be conducted with random-effects models. Cumulative meta-analyses and trial sequential analyses will be performed to assess whether and when firm evidence is reached. Various sensitivity analyses and rigid publication bias analyses will be performed to challenge the consistency and robustness of results. We will also grade the quality of evidence with the GRADE system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval is not required in this study. The findings will be submitted for publication in a peer-reviewed journal and also presented at relevant national and international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>PROSPERO CRD42014014699.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2014-007215","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T21:22:18Z","timestamp":1429651338000},"page":"e007215","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials"],"prefix":"10.1136","volume":"5","author":[{"given":"Yupeng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Urology Oncology, The Third Affiliated Hospital, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, School of Public Health, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Third Affiliated Hospital, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Third Affiliated Hospital, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Third Affiliated Hospital, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Colorectal Cancer Surgery, The Third Affiliated Hospital, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer Surgery, The Third Affiliated Hospital, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yashuang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,4,21]]},"reference":[{"key":"2025121220065772000_5.4.e007215.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"2025121220065772000_5.4.e007215.2","unstructured":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. http:\/\/globocan.iarc.fr"},{"key":"2025121220065772000_5.4.e007215.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21235"},{"key":"2025121220065772000_5.4.e007215.4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1743-7563.2010.01275.x","article-title":"Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer","volume":"6","author":"Aghili","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025121220065772000_5.4.e007215.5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","article-title":"Superficial bladder cancer: progression and recurrence","volume":"130","author":"Heney","year":"1983","journal-title":"J Urol"},{"key":"2025121220065772000_5.4.e007215.6","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-1089"},{"key":"2025121220065772000_5.4.e007215.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70539-4"},{"key":"2025121220065772000_5.4.e007215.8","first-page":"3279","article-title":"Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"21","author":"Oster","year":"2013","journal-title":"Support Care Cancer"},{"key":"2025121220065772000_5.4.e007215.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-2094-y"},{"key":"2025121220065772000_5.4.e007215.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp043801"},{"key":"2025121220065772000_5.4.e007215.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm442"},{"key":"2025121220065772000_5.4.e007215.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70122-X"},{"key":"2025121220065772000_5.4.e007215.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70054-1"},{"key":"2025121220065772000_5.4.e007215.14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025121220065772000_5.4.e007215.15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-480"},{"key":"2025121220065772000_5.4.e007215.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.2167"},{"key":"2025121220065772000_5.4.e007215.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70226-7"},{"key":"2025121220065772000_5.4.e007215.18","doi-asserted-by":"publisher","DOI":"10.1080\/02841860801964988"},{"key":"2025121220065772000_5.4.e007215.19","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1384"},{"key":"2025121220065772000_5.4.e007215.20","doi-asserted-by":"publisher","DOI":"10.1080\/02841860410032885"},{"key":"2025121220065772000_5.4.e007215.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808063390601"},{"key":"2025121220065772000_5.4.e007215.22","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2010.n.062"},{"key":"2025121220065772000_5.4.e007215.23","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","article-title":"Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial","volume":"15","author":"Denham","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025121220065772000_5.4.e007215.24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/cas.12448","article-title":"Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group","volume":"105","author":"Murakami","year":"2014","journal-title":"Cancer Sci"},{"key":"2025121220065772000_5.4.e007215.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.6500"},{"key":"2025121220065772000_5.4.e007215.26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23783"},{"key":"2025121220065772000_5.4.e007215.27","doi-asserted-by":"publisher","DOI":"10.1007\/BF02698044"},{"key":"2025121220065772000_5.4.e007215.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"2025121220065772000_5.4.e007215.29","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.ejca.2013.01.021","article-title":"Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2013","journal-title":"Eur J Cancer"},{"key":"2025121220065772000_5.4.e007215.30","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121220065772000_5.4.e007215.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040783"},{"key":"2025121220065772000_5.4.e007215.32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","article-title":"The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials","volume":"48","author":"Yan","year":"2012","journal-title":"Eur J Cancer"},{"key":"2025121220065772000_5.4.e007215.33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.6004\/jnccn.2010.0020","article-title":"Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials","volume":"8","author":"Mauri","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"2025121220065772000_5.4.e007215.34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603661"},{"key":"2025121220065772000_5.4.e007215.35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1756-8722-6-80","article-title":"Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis","volume":"6","author":"He","year":"2013","journal-title":"J Hematol Oncol"},{"key":"2025121220065772000_5.4.e007215.36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070044"},{"key":"2025121220065772000_5.4.e007215.37","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0261"},{"key":"2025121220065772000_5.4.e007215.38","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","volume":"5","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121220065772000_5.4.e007215.39","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group's Bisphosphonate Working Group (EBCTCG). Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. Abstract S4\u201307. The 36th Annual San Antonio Breast Cancer Symposium (SABCS); 2013."},{"key":"2025121220065772000_5.4.e007215.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2025121220065772000_5.4.e007215.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"key":"2025121220065772000_5.4.e007215.42","unstructured":"ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/"},{"key":"2025121220065772000_5.4.e007215.43","unstructured":"EU Clinical Trials Register. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search"},{"key":"2025121220065772000_5.4.e007215.44","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jclinepi.2012.11.007","article-title":"Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error","volume":"66","author":"Miladinovic","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2025121220065772000_5.4.e007215.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013"},{"key":"2025121220065772000_5.4.e007215.46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036298","article-title":"Quantitative methods in the review of epidemiologic literature","volume":"9","author":"Greenland","year":"1987","journal-title":"Epidemiol Rev"},{"key":"2025121220065772000_5.4.e007215.47","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025121220065772000_5.4.e007215.48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2025121220065772000_5.4.e007215.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00455.x"},{"key":"2025121220065772000_5.4.e007215.50","unstructured":"Sch\u00fcnemann H , Bro\u017cek J , Guyatt G , et al . GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. http:\/\/www.guidelinedevelopment.org\/handbook"},{"key":"2025121220065772000_5.4.e007215.51","unstructured":"Liu YP , Zhang Y , Zhao S , et al . Bisphosphonate and risk of cancer recurrence: a systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. PROSPERO 2014:CRD42014014699. http:\/\/www.crd.york.ac.uk\/PROSPERO_REBRANDING\/display_record.asp?ID=CRD42014014699"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-007215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:07:05Z","timestamp":1765598825000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-007215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,21]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1136\/bmjopen-2014-007215"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-007215","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}